Bullish case
$520 to $545
More likely if Repatha, EVENITY, Tepezza, UPLIZNA, BLINCYTO, and IMDELLTRA keep growing, MariTide Phase 3 evidence strengthens, biosimilar erosion stays manageable, debt falls, and investors pay about 19x forward earnings.
Amgen Inc. research snapshot
AMGN AI Stock Analysis
AMGN AI stock analysis currently reads Amgen Inc. as a large-cap biotechnology company with durable biologics franchises, a broad rare disease and oncology portfolio, rising Q1 2026 revenue, heavy post-Horizon debt, and important patent and pipeline execution risk. At the July 8, 2026 data cutoff, AMGN traded near $367.90 with an implied market capitalization of about $198.67 billion. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$367.90
Market cap
$198.67 billion
AI score
69 / 100
Rating
High-quality biotech, valuation discipline required
Trend status
Positive long-term trend with mixed short-term risk score
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
Research quality check
- information Richness
- A-level information richness. Amgen has decades of filings, detailed product sales tables, quarterly earnings releases, broad technical coverage, and third-party financial datasets.
- bias Check
- The main AI bias risk is repeating the consensus view that mature biologics, Horizon assets, and MariTide can offset patent pressure without testing debt, payer pressure, and clinical execution risk.
- ai Confidence
- High for reported financials, Q1 2026 product data, balance sheet figures, and market cap math. Medium for forward scenarios because drug pricing, biosimilars, trial data, and FDA events can reprice AMGN quickly.
- investment Certainty
- Medium. The business is researchable and cash generative, but the margin of safety depends on pipeline productivity, patent erosion, and whether the market multiple already prices successful execution.
Quick verdict table
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Amgen sells biologic and specialty medicines across general medicine, rare disease, inflammation, oncology, and established products. | High |
| Moat | The moat comes from biologics know-how, patents, clinical evidence, physician trust, manufacturing scale, reimbursement access, and a global commercial base. | Medium-high |
| Management | Robert A. Bradway and the team should be judged by Horizon integration, debt reduction, MariTide execution, capital allocation, and replacement of aging franchises. | Medium |
| Financial trend | FY2025 revenue rose 10% to $36.751 billion, and Q1 2026 revenue rose 6% to $8.6 billion while free cash flow improved to $1.5 billion. | High |
| Valuation | At $367.90, AMGN traded near 25.9x FY2025 GAAP EPS, 16.5x midpoint 2026 non-GAAP EPS guidance, and 24.6x FY2025 free cash flow per share. | Medium-high |
| Technical trend | Price was above short and long moving averages, but one technical score source still rated the stock Sell at 47, so momentum is constructive but not one-sided. | Medium |
| Risk level | Main risks are Prolia and Xgeva biosimilar erosion, Enbrel price pressure, drug pricing regulation, heavy debt, clinical setbacks, and acquisition integration. | Medium-high |
| AI confidence | High for descriptive research and calculations. Lower for exact price outcomes because biotech stocks move around trial, patent, reimbursement, and regulatory events. | High data confidence |
| Investment certainty | Medium certainty. AMGN is high quality, but a buy decision depends on price discipline and comfort with patent-cycle and pipeline risk. | Medium |
AMGN AI stock forecast
AMGN AI Stock Forecast Scenarios
The AMGN AI stock forecast uses scenario math around the $367.90 quote and Amgen 2026 non-GAAP EPS guidance. The audited three-year framework produced a bearish area near $237, a base area near $401, and a bullish area near $534 before dividends.
Base case
$390 to $410
More likely if non-GAAP EPS compounds around low single digits to mid single digits, the portfolio offsets aging products, and the market values Amgen near a mid-teens earnings multiple.
Bearish case
$230 to $245
More likely if Prolia, Xgeva, or Enbrel erosion is worse than expected, MariTide disappoints, payer pressure reduces price, debt limits flexibility, or the market compresses AMGN toward a low-teens multiple.
AMGN AI technical analysis
AMGN AI Technical Analysis
AMGN AI technical analysis is constructive but mixed as of the July 8, 2026 cutoff. Financhill listed AMGN near $366.44, above its 8-day EMA, 20-day EMA, 50-day EMA, and 200-day simple moving average, while also assigning a 47 score and Sell rating.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $367.90 | Quote and market cap snapshot used for July 8, 2026 research and market cap math. |
| Near support | $361 to $362 | The 8-day EMA near $361.52 is the closest moving-average support in the Financhill technical snapshot. |
| Secondary support | $353 to $354 | The 20-day EMA near $353.56 is the next short-term support area if the first support fails. |
| Intermediate support | $347 to $348 | The 50-day EMA near $347.75 helps define whether the medium-term trend remains intact. |
| Long-term support | $336 | The 200-day simple moving average near $336.07 is the major trend reference. |
| Resistance | $391 | Financhill listed a 52-week high near $391.29, which is the visible upside level to monitor. |
| Momentum | Score 47 / 100 | Financhill rated AMGN Sell at 47 even though the moving-average stack was positive, so the signal mix is not clean. |
| Volume | Liquid large-cap biotech trading | Volume should be compared with earnings, FDA, clinical data, and reimbursement news because biotech volume can spike around event risk. |
| Volatility | Event-sensitive large-cap biotech volatility | Expect larger moves around MariTide data, biosimilar updates, guidance changes, and drug pricing headlines. |
| Invalidation | Close below $347, then $336 | A break below the 50-day EMA would weaken the swing setup. A decisive break below the 200-day average would challenge the long-term trend. |
AMGN AI trading strategy
AMGN AI Trading Strategy Framework
The AMGN AI trading strategy is a rules-based framework for a mature biotech with cash flow, debt, patent-cycle risk, and pipeline optionality. It is not personal advice and should be paired with live quotes, filings, position sizing, and clinical or regulatory event checks.
Trend-following setup
Watch for AMGN to hold above the 50-day EMA and build toward the $391 52-week high with confirming volume and no new negative drug or guidance news.
A close below the $347 to $348 area should invalidate the swing setup. A close below the 200-day average should force a full thesis review.
Mean-reversion setup
If AMGN pulls back toward the 20-day or 50-day EMA without a new patent, trial, or guidance problem, compare the price drop with Q1 product trends and cash flow evidence.
Do not average down through drug-specific bad news. Patent, clinical, and reimbursement events can turn a technical support level into a fundamental break.
Fundamental monitor
Track Repatha, EVENITY, Tepezza, UPLIZNA, BLINCYTO, IMDELLTRA, Prolia, Xgeva, Enbrel, MariTide Phase 3 progress, debt outstanding, free cash flow, dividend coverage, and 2026 EPS guidance.
Reduce confidence if EPS growth depends mainly on multiple expansion, cost cuts, or adjustments rather than product-level growth and debt reduction.
Investment research summary
Four-master Research Compression
Business essence
Amgen converts biologic science, clinical proof, regulatory approvals, manufacturing reliability, and payer access into recurring medicine revenue for serious diseases.
Moat
The moat is strongest where biologics expertise, patents, high-quality trial data, manufacturing scale, prescriber familiarity, and payer relationships reinforce each other. It narrows when exclusivity expires or a rival drug offers better efficacy, safety, convenience, or price.
Munger risk inversion
The thesis fails if mature franchises erode faster than new products grow, if MariTide or other late-stage programs disappoint, if payer pressure cuts net prices, or if Horizon-related debt absorbs too much owner cash.
Management
Management has built a broad biotech portfolio and integrated Horizon assets, but future judgment rests on debt reduction, disciplined buybacks, dividend coverage, and the return on large R&D and acquisition spending.
Industry trend
Biotech benefits from aging populations, biologics innovation, obesity and cardiometabolic demand, oncology progress, and rare disease treatment, but it faces patent cliffs, biosimilars, price controls, and binary clinical outcomes.
Valuation and margin of safety
AMGN is not priced as a broken patent-cliff story. Margin of safety depends on whether 2026 and 2027 earnings can absorb competition, debt service, and pipeline uncertainty without a lower valuation multiple.
Source-backed data
AMGN Data Table
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| AMGN price | $367.90 | Market quote snapshot and market cap math | July 8, 2026 |
| Market capitalization | $198.67 billion, verified as $367.90 x 540 million shares | financial_rigor.py market cap verification | July 8, 2026 |
| FY2025 revenue | $36.751 billion | Amgen FY2025 release, Macrotrends, and StockAnalysis | July 8, 2026 |
| FY2025 net income | $7.711 billion | Amgen FY2025 release and Macrotrends cross-check | July 8, 2026 |
| Q1 2026 revenue and non-GAAP EPS | $8.6 billion revenue, $5.15 non-GAAP diluted EPS | Amgen Q1 2026 earnings release | July 8, 2026 |
| Q1 2026 cash and debt | $12.0 billion cash and cash equivalents, $57.3 billion debt outstanding, about $45.3 billion net debt | Amgen Q1 2026 release and 10-Q snapshot | July 8, 2026 |
| 2026 guidance | $37.0 billion to $38.4 billion revenue, $21.60 to $23.00 non-GAAP EPS | Amgen FY2025 results release | July 8, 2026 |
| Technical moving averages | 8-day EMA $361.52, 20-day EMA $353.56, 50-day EMA $347.75, 200-day SMA $336.07 | Financhill AMGN technical analysis | July 8, 2026 |
| 52-week range | $269.77 to $391.29 | Financhill AMGN technical analysis | July 8, 2026 |
| Scenario valuation audit | Bear $236.8, base $401.4, bull $533.7 from financial_rigor.py | financial_rigor.py three-scenario model | July 8, 2026 |
Frequently Asked Questions
Read the ABBV AI stock analysisCompare with AMZN AI stock analysisExplore the AI Stock PickerBuild an AI trading strategy
This AMGN AI stock analysis page is an informational tool only. It is not investment advice, a recommendation, or a promise of future returns. Forecasts are scenario-based estimates from available public data and may be wrong. Always verify live prices, filings, tax considerations, and risk limits before making investment decisions.